Sonia Partap

Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery Clinical Professor, Pediatrics

Clinical Focus

Neurology - Child Neurology
Pediatric Neuro-Oncology

Academic Appointments

Clinical Professor, Neurology & Neurological Sciences
Clinical Professor (By courtesy), Neurosurgery
Clinical Professor, Pediatrics
Member, Maternal & Child Health Research Institute (MCHRI)

Administrative Appointments

Pediatric Neuro-Oncology Fellowship Director, Stanford (2012 - Present)
Program Director, Neuro-Oncology Fellowship (UCNS), Stanford (2020 - Present)

Boards, Advisory Committees, Professional Organizations

Councilor of the West, Child Neurology Society (2020 - 2022)
Pediatric Representative, American Academy of Neurology, Section of Neuro-Oncology (2015 - Present)
Member, Executive Committee, Section of Neurology, American Academy of Pediatrics (2012 - 2018)
Treasurer (elect), Brain Tumor Epidemiology Consortium (2012 - 2014)

Professional Education

Medical Education: University of Missouri Kansas City School of Medicine Registrar (2000) MO
Residency: Brown University Hospitals (2002) RI
Residency: Childrens Hospital and Regional Medical Center Fellowships (2006) WA
Fellowship:, Packard Children's & Stanford Hospital, Neuro-Oncology (2007)
Masters:, Stanford University, Epidemiology (2009)
Board Certification: American Board of Psychiatry and Neurology, Neurology - Child Neurology (2007)
Board Certification: American Board of Pediatrics, Pediatrics (2007)
Board Certification: United Council for Neurologic Subspecialties, Neuro-Oncology (2011)

Contact

Administrative Contact Julie Ng Administrative Assistant julieng@stanford.edu Tel: 650-736-0885

Clinical Pediatric Oncology Clinic 725 Welch Rd Ste 160 Palo Alto CA 94304 Tel: (650) 497-8953 Fax: (650) 497-8101
Clinical Child Neurology 730 Welch Rd Ste 206 Palo Alto CA 94304 Tel: (650) 723-0993 Fax: (650) 721-6350
Clinical Stanford Children's Health Specialty Services Menlo Park 321 Middlefield Rd Ste 225 Menlo Park CA 94025 Tel: (650) 723-0993 Fax: (650) 721-6350

Current Research and Scholarly Interests

My research interests involve the epidemiology, treatment and diagnosis of pediatric and young adult brain tumors. I am also interested in long-term neurologic effects and designing clinical trials to treat brain and spinal cord tumors.

Clinical Trials

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Not Recruiting
More
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Recruiting
More
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors Recruiting
More
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas Recruiting
More
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
Lead Sponsor
Stanford Investigators
- Michelle Monje
- Sonia Partap
View full details
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Recruiting
More
This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Lead Sponsor
Stanford Investigators
- Michelle Monje
- Sonia Partap
View full details
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG) Recruiting
More
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Lead Sponsor
Stanford Investigators
View full details
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Not Recruiting
More
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Recruiting
More
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma (HGG), medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG).
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Recruiting
More
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system, and may interfere with the ability of tumor cells to grow and spread.
Lead Sponsor
Stanford Investigators
View full details
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Not Recruiting
More
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse. Currently, only Stratum 2 is enrolling patients.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Recruiting
More
This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with recurrent or refractory AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT will receive alisertib as part of age- and risk-adapted chemotherapy. Radiation therapy will be given to children ≥12 months of age. Patients with AT/RT and concurrent extra-CNS MRT are eligible. Alisertib will be administered as a single agent on days 1-7 of each 21-day cycle in all recurrent patients enrolled on Stratum A. For the patients on the newly diagnosed strata (B, C or D), alisertib will be administered in sequence with chemotherapy and radiotherapy. This study has 3 primary strata: (A) children with recurrent/progressive AT/RT or extra-CNS MRT, (B) children < 36 months-old with newly diagnosed AT/RT, (C) children > 36 months old with newly diagnosed AT/RT. Children with concurrent MRT will be treated according to age and risk stratification schemes outlined for strata B and C and will have additional treatment for local control. Children with synchronous AT/RT will be treated with age and CNS risk-appropriate therapy, and also receive surgery and/or radiation therapy for local control of the non-CNS tumor. PRIMARY OBJECTIVES - To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive AT/RT (atypical teratoid rhabdoid tumor in the CNS) (Stratum A1) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population. - To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive extra-CNS MRT (malignant rhabdoid tumor outside the CNS) (Stratum A2) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population. - To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis with no metastatic disease (Stratum B1) treated with alisertib in sequence with induction and consolidation chemotherapy and radiation therapy (depending on age) and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. - To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis, with metastatic disease (Stratum B2) treated with alisertib in sequence with induction and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. - To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with no metastatic disease and gross total resection or near total resection (Stratum C1) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. - To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with metastatic or residual disease (Stratum C2) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population. - To characterize the pharmacokinetics and pharmacodynamics of alisertib in pediatric patients and to relate drug disposition to toxicity. SECONDARY OBJECTIVES - To estimate the duration of objective response and PFS in patients with recurrent/progressive AT/RT and MRT (Strata A1 and A2). - To estimate PFS and OS distributions in patients with newly diagnosed AT/RT (Strata B1, B2, B3, C1 and C2). - To describe toxicities experienced by patients treated on this trial, specifically any toxicities of alisertib when administered as a single agent or in combination with other therapy over multiple courses and toxicities related to proton or photon radiation therapy. - To describe the patterns of local and distant failure in newly diagnosed patients (Strata B1, B2, B3, C1 and C2). Local control relative to primary-site radiation therapy, with criteria for infield, marginal, or distant failure will also be reported descriptively.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Not Recruiting
More
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: - To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. - To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. - To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. - To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: - WNT (Strata W): positive for WNT biomarkers - SHH (Strata S): positive for SHH biomarkers - Non-WNT Non-SHH, Failed, or Indeterminate (Strata N): negative for WNT and SHH biomarkers or results are indeterminable Participants will then be assigned to a clinical risk group (low, standard, intermediate, or high) based on assessment of: - How much tumor is left after surgery - If the cancer has spread to other sites outside the brain [i.e., to the spinal cord or within the fluid surrounding the spinal cord, called cerebrospinal fluid (CSF)] - The appearance of the tumor cells under the microscope - Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)

Stanford is currently not accepting patients for this trial. For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Lead Sponsor
Stanford Investigators
View full details
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701) Not Recruiting
More
The primary objective of this study is to examine the safety and tolerability of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA) who previously participated in ISIS 396443-CS1 (NCT02865109). The secondary objective was to examine the plasma pharmacokinetics of a single dose of ISIS 396443 administered intrathecally to participants with SMA who previously participated in ISIS 396443-CS1.

Stanford is currently not accepting patients for this trial. For more information, please contact Shirley Paulose, 650-724-3792.
Lead Sponsor
Stanford Investigators
- Sonia Partap
View full details
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma Not Recruiting
More
This multi-institutional study will prospectively collect tumor and constitutional tissue samples from patients with diffuse brainstem glioma and other types of brainstem gliomas either during therapy or at autopsy to perform an extensive analysis of genetic and molecular abnormalities in these tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Michelle Monje, .
Lead Sponsor
Stanford Investigators
- Paul Graham Fisher, MD
- Sonia Partap
View full details
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Not Recruiting
More
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Stanford is currently not accepting patients for this trial. For more information, please contact Prianka Kumar, 650-724-3866.
Lead Sponsor
Stanford Investigators
View full details

All Publications

Profiles With Related Publications

close
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma
Clinical Focus
Cancer > Lymphoma, Burkitt's Lymphoma, Hodgkin's Disease, Investigational Therapeutics, Lymphoma , Mycosis Fungoides, Non-Hodgkin's Lymphoma, Oncology (Cancer), Plasmacytoma, Waldenstrom's Macroglobulinemia , Medical Oncology
Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

648 Total Publications
close
Michael Amylon

Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Research Interests
Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.

104 Total Publications
close
Patrick Barnes

Professor of Radiology (Pediatric Radiology) at the Stanford University Medical Center, Emeritus
Research Interests
Advanced imaging, including magnetic resonance imaging, of injury to the developing central nervous system; including fetal, neonatal, infant and young child; and, including nonaccidental injury (e.g. child abuse).

See Biosketch for details.

193 Total Publications
close
Melissa L Bondy

Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics

443 Total Publications
close
Saurabh Dahiya, MD, FACP

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Clinical Focus
Blood and Marrow Transplantation, Cellular Therapy, Hematology

59 Total Publications
close
Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus
Research Interests
Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

169 Total Publications
close
Sarah S. Donaldson, MD

Catharine and Howard Avery Professor in the School of Medicine, Emerita
Research Interests
Combined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases

303 Total Publications
close
Nancy Fischbein

Professor of Radiology and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) , of Neurology, of Neurosurgery & of Radiation Oncology
Clinical Focus
Neuroradiology

210 Total Publications
close
Paul Graham Fisher, MD

Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Clinical Focus
Cancer > Neuro Oncology, Neurology - Child Neurology, Neuro-Oncology, Neurology
Research Interests
Clinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies, and childhood headaches.

273 Total Publications
close
Seunggu J Han

Clinical Associate Professor, Neurosurgery

77 Total Publications
close
Steven Hancock, MD

Professor of Radiation Oncology (Radiation Therapy), Emeritus
Clinical Focus
Cancer > Cutaneous (Dermatologic) Oncology, Cancer > Radiation Oncology, Cancer > Urologic Oncology, CNS Cancers, Prostate Cancer, Bladder cancer, Kidney Cancer, Lymphomas, Radiation Therapy, Radiation Injuries, Stereotactic Radiosurgery, Stereotactic Ablative Body Radiotherapy, Acoustic Neuroma, Meningioma, Radiation Oncology
Research Interests
Outcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
General adult and pediatric radiation therapy.

184 Total Publications
close
Melanie Hayden Gephart

Professor of Neurosurgery and, by courtesy, of Neurology
Clinical Focus
Neurosurgery

149 Total Publications